Y.D. More Investments Ltd Sells 126,959 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Y.D. More Investments Ltd lowered its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,254,591 shares of the company’s stock after selling 126,959 shares during the period. Takeda Pharmaceutical makes up 3.6% of Y.D. More Investments Ltd’s holdings, making the stock its 6th biggest holding. Y.D. More Investments Ltd’s holdings in Takeda Pharmaceutical were worth $17,903,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $28,000. Lindbrook Capital LLC increased its holdings in Takeda Pharmaceutical by 40.6% during the 4th quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock worth $58,000 after purchasing an additional 1,174 shares during the period. Headlands Technologies LLC acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $85,000. Hexagon Capital Partners LLC grew its holdings in Takeda Pharmaceutical by 65.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 5,548 shares of the company’s stock worth $86,000 after acquiring an additional 2,199 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Takeda Pharmaceutical by 91.1% in the 4th quarter. Blue Trust Inc. now owns 5,837 shares of the company’s stock valued at $91,000 after purchasing an additional 2,782 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.8 %

Shares of NYSE:TAK traded up $0.11 on Wednesday, hitting $13.19. 1,293,552 shares of the company’s stock were exchanged, compared to its average volume of 1,799,791. The firm’s 50-day moving average is $13.99 and its 200 day moving average is $14.15. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06. The company has a market capitalization of $41.74 billion, a PE ratio of 19.83, a P/E/G ratio of 3.00 and a beta of 0.53. Takeda Pharmaceutical Company Limited has a 1-year low of $13.01 and a 1-year high of $17.11.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. Sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.